Pharmacological compounds aimed at correcting abnormal RyR1 function may be of benefit not only in RYR1-related neuromuscular disorders but potentially also a wider range of non-skeletal muscle disorders. This evidence concerns the gene RYR1 and skeletal muscle disorder.